Published in Women's Health Weekly, July 17th, 2003
The new study, presented June 19, 2003, at ENDO 2003, the 85th annual meeting of The Endocrine Society (ENDO), examined the long-term safety profile and sustained efficacy of Actonel in the treatment of postmenopausal osteoporosis.
"Osteoporosis is treated over a number of years, so long-term protection against fractures is critical," said Jean-Marc Kaufman, MD, PhD, Unit for Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Belgium. "This is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly